Kunimasa K, Oka T, Hara S, et al. - Given that treatment with osimertinib is related to a risk of cancer therapy-related cardiac dysfunction (CTRCD) for patients with EGFR-mutated non–small cell lung cancer (NSCLC), researchers sought to gain clarity on the clinical features of patients with CTRCD lined with osimertinib. There were 183 advanced EGFR-mutated NSCLC cases managed with osimertinib monotherapy were analyzed. Following osimertinib therapy, a significant reduction in LVEF was noted, from a mean value of 69% at baseline to 66%. LVEF remained low during osimertinib therapy, but no further reductions were seen. Six out of 8 CTRCD patients recovered after discontinuation, dose reduction, or switching to another EGFR tyrosine kinase inhibitor. A significant predictor of CTRCD, as revealed in multivariate analysis, was a history of heart disease. Findings demonstrated a dose-independent relationship between osimertinib and the risk of CTRCD, which was reversible with drug withdrawal.